AbbVie, J&J concede a failure for blockbuster Imbruvica in their PhIII shot at pancreatic cancer
Pancreatic cancer has beaten another Phase III effort aimed at improving the prospects of patients fighting the disease.
Just ahead of the 3-day weekend, AbbVie $ABBV and their partners at J&J $JNJ announced that the late-stage study of Imbruvica combined with a pair of chemo drugs could do no better than the chemo approach alone in improving either progression-free or overall survival for pancreatic cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.